Securities
Jan. 11, 2023
Pomerantz asks to lead securities class action over COVID drug
Jennifer Pafiti, a partner at Pomerantz’s Los Angeles office, argued In the motion filed Monday in federal court in San Francisco that the financial losses incurred by her client, George Fareed, merit the firm being named lead counsel, and Fareed lead plaintiff. The defendants are Eiger Biopharmaceuticals Inc., Chief financial Officer Sriram Ryali, and former CEO David A. Cory.
Pomerantz LLP has asked to be named lead counsel in a securities class action against a pharmaceutical company and two of its executives accused of misrepresenting the potential for FDA authorization of one a COVID-19 treatments, leading to a plunge in stock value.
Jennifer Pafiti, a partner at Pomerantz’s Los Angeles office, argued In the motion filed Monday in federal court in San Francisco that the financial losses incurred by her clien...
For only $95 a month (the price of 2 article purchases)
Receive unlimited article access and full access to our archives,
Daily Appellate Report, award winning columns, and our
Verdicts and Settlements.
Or
$795 for an entire year!
Or access this article for $45
(Purchase provides 7-day access to this article. Printing, posting or downloading is not allowed.)
Already a subscriber?
Sign In